DrugPatentWatch Database Preview
CANASA Drug Profile
» See Plans and Pricing
Which patents cover Canasa, and when can generic versions of Canasa launch?
Canasa is a drug marketed by Allergan and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fourteen patent family members in thirteen countries.
The generic ingredient in CANASA is mesalamine. There are twenty-eight drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the mesalamine profile page.
US ANDA Litigation and Generic Entry Outlook for Canasa
A generic version of CANASA was approved as mesalamine by PERRIGO ISRAEL on September 17th, 2004.
Summary for CANASA
| International Patents: | 14 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 160 |
| Clinical Trials: | 2 |
| Patent Applications: | 2,331 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CANASA |
| Drug Sales Revenues: | Drug sales revenues for CANASA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CANASA |
| DailyMed Link: | CANASA at DailyMed |
Recent Clinical Trials for CANASA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Sandoz | Phase 3 |
| Axcan Pharma | Phase 3 |
Pharmacology for CANASA
| Drug Class | Aminosalicylate |
Paragraph IV (Patent) Challenges for CANASA
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| CANASA | SUPPOSITORY;RECTAL | mesalamine | 021252 | 2013-05-24 |
US Patents and Regulatory Information for CANASA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | CANASA | mesalamine | SUPPOSITORY;RECTAL | 021252-002 | Nov 5, 2004 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
| Allergan | CANASA | mesalamine | SUPPOSITORY;RECTAL | 021252-002 | Nov 5, 2004 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
| Allergan | CANASA | mesalamine | SUPPOSITORY;RECTAL | 021252-001 | Jan 5, 2001 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CANASA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Mexico | 2012006902 | Start Trial |
| Mexico | 2012006902 | Start Trial |
| European Patent Office | 2512443 | Start Trial |
| Japan | 2013514979 | Start Trial |
| Canada | 2784772 | Start Trial |
| Singapore | 181169 | Start Trial |
| South Korea | 20120104604 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
